There is considerable interest in therapeutically targeting VEGF-C and/or VEGF-D in the clinic to block their action and thereby restrict angiogenesis, lymphangiogenesis, or vascular leakage in cancer, macular degeneration, and other conditions (9, 50, –, 53). This evidence concerns the gene VEGFD and macular degeneration.